Physician profile
Beau Brouillette
NPI 1457353682
$6,851.70
in general payments reported to CMS, 2019-2025
34 companies · $892 in 2025
The $892 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $1,177 · 2021: $997 · 2022: $793 · 2023: $920 · 2024: $723 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,534.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,192.88 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $968.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $793.03 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $462.73 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $426.61 | 2021-2025 | Vraylar, Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $414.51 | 2020-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $391.94 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $330.85 | 2021-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $280.27 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $202.80 | 2020-2023 | |
| Allergan, INC. | $164.13 | 2019-2020 | |
| Mylan Specialty L.P. | $160.95 | 2019-2024 | Yupelri |
| Boston Scientific Corporation | $158.91 | 2021-2025 | General - Vascular Intervention |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.47 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $98.24 | 2019-2022 |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beau Brouillette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.